IMU Biosciences funding, valuation and investors

Overview

IMU Biosciences is a London-based biotechnology company decoding the human immune system at unprecedented resolution for diagnostics, patient stratification, and therapeutic development. Founded in 2019 by immunologists and computational biologists from the Francis Crick Institute and King's College London, IMU combines high-fidelity multi-omic profiling with proprietary machine learning on what it describes as the world's largest immune dataset — scaling past 25,000 individuals in 2026. The company closed an oversubscribed Series A extension above $53M (£40M) in June 2026 co-led by IQ Capital and Molten Ventures, with the British Business Bank investing £5M. Proceeds fund clinical programs in stem-cell transplantation, solid-organ transplantation, and the MANIFEST immuno-oncology consortium.

Why IMU Biosciences is interesting

IMU measures 100M+ immune data points from a single blood sample and closed an oversubscribed $53M+ Series A extension — positioning immune profiling as a universal clinical standard.

Product & use cases

IMU's discovery platform profiles immune states from a standard blood draw using multi-omic analysis and AI/ML, generating clinically actionable immune signatures for pharma partners, biotech collaborators, and hospital systems.

• Patient stratification for cancer immunotherapy response (MANIFEST consortium)
• Immune monitoring in stem-cell and solid-organ transplantation
• Biomarker discovery and drug-target identification for pharma partners
• Population-scale immune atlases linking health and disease states

Key facts

• Series A extension (June 2026): $53M+ co-led by IQ Capital and Molten Ventures — British Business Bank £5M
• 100M+ immune data points measured from a single blood sample
• Immune dataset scaling to 25,000+ individuals in 2026
• Active clinical programs: transplantation and MANIFEST immuno-oncology consortium
• Founded by Francis Crick Institute and King's College London researchers

Funding history (newest first)

Competitive landscape

Edge: Proprietary immune dataset at 25,000+ individuals with 100M+ data points per sample — founders' decade of Crick/KCL immunology expertise anchors clinical credibility.

Immune profiling is fragmented between instrument vendors, sequencing specialists, and platform biotechs. IMU bets a universal immune standard — like genomics reference panels — unlocks precision medicine across transplantation, oncology, and autoimmunity. Clinical program traction in the UK differentiates it from pure discovery tools.

• Adaptive Biotechnologies adjacent

  Immune-receptor sequencing leader (TCR/BCR); different modality focus vs. IMU's systems-level multi-omic profiling.

• 10x Genomics (single-cell) adjacent

  Single-cell tools vendor; IMU builds end-to-end immune discovery platform and datasets, not just instruments.

• Internal pharma immunology programs alternative

  Large pharmas run in-house immune profiling; IMU sells standardized external platform and data access.

• Isoplexis direct

  Single-cell functional proteomics for immune profiling; competes for pharma biomarker budgets.

Notable stories

• IMU's founders spent over a decade at the Francis Crick Institute and King's College London before commercializing immune profiling — moving from 'simplistic, fragmented' immune views to systems-level 'high definition' maps (company positioning).
• Total capital raised reached $60M after the June 2026 extension — oversubscribed demand reflected investor appetite for data-rich UK platform biology (AllSci, June 2026).

Industries

Related funding articles

Venture Capital Tracker pieces that cover IMU Biosciences's financing or category context.

• IMU Biosciences's $53M+: Decoding the Immune System at Scale